文献速递神经免疫认知障碍与痴呆

慢性活动性多发性硬化病灶与残疾的体内关联研究

Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo.
PubMed 文献 · JAMA Neurol · 2019-01-01

该研究基于209例多发性硬化患者的前瞻性队列,利用7T或3T磁敏感脑MRI识别慢性活动性病灶(顺磁性边缘病灶),发现56%患者至少有一个边缘病灶,且边缘病灶数量≥4个与更早达到运动与认知残疾相关。纵向分析显示边缘病灶体积稳定或增大(+2.2%/年),而无边缘病灶缩小(-3.6%/年),提示持续组织损伤。

要点

  • 56%的多发性硬化患者存在至少一个顺磁性边缘病灶,即使接受有效治疗。
  • 边缘病灶数量≥4个与更早出现运动和认知残疾相关。
  • 边缘病灶体积稳定或增大(+2.2%/年),而无边缘病灶缩小(-3.6%/年)。

核心结论

  • 慢性活动性病灶常见,与更侵袭性疾病相关,持续造成组织损伤,且即使在接受有效疾病修饰治疗的患者中也会出现。

研究设计与样本

  • 前瞻性临床/放射学队列纳入209例多发性硬化患者(2010 McDonald标准,年龄≥18岁),其中192例可解读MRI纳入主要分析。
  • 放射学/病理学分析:1例进展型多发性硬化患者尸检的10个扩张性边缘病灶。
  • 回顾性纵向放射学研究:23例患者每年MRI随访≥10年,评估27个边缘病灶与27个无边缘病灶的演变。

主要发现

  • 边缘病灶≥4个的患者更早达到运动和认知残疾。
  • 边缘病灶患者脑、白质和基底节归一化体积更低。
  • 所有10个体内扩张的边缘病灶均显示慢性活动性炎症。

临床怎么用

  • 基于磁敏感MRI识别顺磁性边缘病灶有助于识别更具侵袭性病程的多发性硬化患者。
  • 边缘病灶可作为针对病灶周围慢性炎症的治疗靶点,支持规划MRI终点临床试验。

局限性

  • 主要分析排除17例(8%)MRI不可解读的患者。
  • 病理分析仅来自1例尸检病例的10个病灶。
  • 纵向放射学分析样本量较小(23例患者,27对病灶)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In multiple sclerosis (MS), chronic active lesions, which previously could only be detected at autopsy, can now be identified on susceptibility-based magnetic resonance imaging (MRI) in vivo as non-gadolinium-enhancing lesions with paramagnetic rims. Pathologically, they feature smoldering inflammatory demyelination at the edge, remyelination failure, and axonal degeneration. To our knowledge, the prospect of long-term in vivo monitoring makes it possible for the first time to determine their contribution to disability and value as a treatment target. OBJECTIVE: To assess whether rim lesions are associated with patient disability and long-term lesion outcomes. DESIGN, SETTING, PARTICIPANTS: We performed 3 studies at the National Institutes of Health Clinical Center: (1) a prospective clinical/radiological cohort of 209 patients with MS (diagnosis according to the 2010 McDonald revised MS criteria, age ≥18 years, with 7-T or 3-T susceptibility-based brain MRI results) who were enrolled from January 2012 to March 2018 (of 209, 17 patients [8%] were excluded because of uninterpretable MRI scans); (2) a radiological/pathological analysis of expanding lesions featuring rims; and (3) a retrospective longitudinal radiological study assessing long-term lesion evolution in 23 patients with MS with yearly MRI scans for 10 years or more (earliest scan, 1992). MAIN OUTCOMES AND MEASURES: (1) Identification of chronic rim lesions on 7-T or 3-T susceptibility-based brain MRI in 192 patients with MS and the association of rim counts with clinical disability (primary analysis) and brain volume changes (exploratory analysis). (2) Pathological characterization of 10 expanding lesions from an adult with progressive MS who came to autopsy after 7 years of receiving serial in vivo MRI scans. (3) Evaluation of annual lesion volume change (primary analysis) and T1 times (exploratory analysis) in 27 rim lesions vs 27 rimless lesions. RESULTS: Of 209 participants, 104 (50%) were women and 32 (15%) were African American. One hundred seventeen patients (56%) had at least 1 rim lesion regardless of prior or ongoing treatment. Further, 84 patients (40%) had no rims (mean [SD] age, 47 [14] years), 66 (32%) had 1 to 3 rims (mean [SD] age, 47 [11] years), and 42 (20%) had 4 rims or more (mean [SD] age, 44 [11] years). Individuals with 4 rim lesions or more reached motor and cognitive disability at an earlier age. Normalized volumes of brain, white matter, and basal ganglia were lower in those with rim lesions. Whereas rimless lesions shrank over time (-3.6%/year), rim lesions were stable in size or expanded (2.2%/year; P < .001). Rim lesions had longer T1 times, suggesting more tissue destruction, than rimless lesions. On histopathological analysis, all 10 rim lesions that expanded in vivo had chronic active inflammation. CONCLUSIONS AND RELEVANCE: Chronic active lesions are common, are associated with more aggressive disease, exert ongoing tissue damage, and occur even in individuals treated with effective disease-modifying therapies. These results prompt the planning of MRI-based clinical trials aimed at treating perilesional chronic inflammation in MS.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Absinta M, Sati P, Masuzzo F, et al. Association of Chronic Active Multiple Sclerosis Lesions With Disability In Vivo. JAMA Neurol. 2019. PMID: 31403674. doi:10.1001/jamaneurol.2019.2399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。